Drug Trial Radar · NCT05876832
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
312
Planned (sponsor's estimate)
Start
Jun 15, 2023
Primary completion
Jul 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the clinical benefit of XY0206 therapy in participants with FLT3-ITD mutated AML who are refractory to or have relapsed after prior AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study is also to investigate the efficacy of XY0206 as assessed by CR/CRh rate in these subjects。
Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
XY0206Drug
Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
Salvage ChemotherapyDrug
Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Interim analysis: Complete remission(CR)/CR with partial hematologic recovery(CRh) rate in the experimental group.Time frame: up to 3 years.
- The final analysis: Overall Survival(OS).Time frame: up to 3 years .
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.